FDA Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Entrectinib

Foundation Medicine, Inc. announced that it received approval from the U.S. Food and Drug Administration (FDA) for the use of FoundationOne®Liquid CDx as a companion diagnostic to identify patients with ROS1-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumors, who do not have a tissue sample available and may be appropriate for treatment with entrectinib. 

For more information, read the Foundation Medicine announcement. 

Posted 1/5/2023